Guide
Is Compounded Semaglutide Legal in 2026?
Yes, under two pathways. 503A patient-specific compounding is not addressed by the FDA's April 2026 proposal; 503B outsourcing is. The shortage pathway ended in 2025, so
Yes, under two pathways. 503A patient-specific compounding is not addressed by the FDA's April 2026 proposal; 503B outsourcing is. The shortage pathway ended in 2025, so the surviving route requires a prescriber to document a clinical difference for the individual patient.
Is compounding this drug legal in 2026?
Compounding semaglutide is lawful under two pathways, and which one applies changes your exposure to a live regulatory decision.
| Pathway | What it is | Current status |
|---|---|---|
| 503A | State-licensed pharmacy compounding for an individual patient against a prescription | Not addressed by the April 2026 bulks proposal |
| 503B | FDA-registered outsourcing facility compounding in batches under cGMP | Subject to the proposal to exclude semaglutide from the bulks list |
The FDA declared the semaglutide shortage resolved in 2025 and enforcement discretion ended. The surviving route requires a prescriber to document a clinical difference for the individual patient — a different dose, or a formulation the approved product does not offer.
More than 130 letters since September 2025, in three waves. Read carefully, the overwhelming majority concern marketing claims rather than what is in the vial. That is a genuine limit on what the letter count tells you about product safety — in both directions.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Which protocols did you capture, and at what price?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $147 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
Flat at every covered dose within each protocol, stated on the provider's own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
What is the salt-form question?
Its sodium and acetate salts are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent of this question.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is Compounded Semaglutide Legal in 2026??
Yes, under two pathways. 503A patient-specific compounding is not addressed by the FDA's April 2026 proposal; 503B outsourcing is. The shortage pathway ended in 2025, so the surviving route requires a prescriber to document a clinical difference for
Which figures did you read yourselves?
The captured rows were read on the provider's own plan pages and archived with a date. Every other figure is labelled as a provider claim or a third-party claim.
Does the price change as the dose increases?
On dose-tiered programmes, yes. The programmes we captured are flat across the full 0.25 to 2.4 mg range, so the advertised figure is also the maintenance figure.
What is the salt-form question?
Semaglutide sodium and acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Compounding Pharmacy Recalls and Warning LettersPharmacies
- Cold-Chain Shipping for Compounded GLP-1sPharmacies
- 503B Outsourcing Facility DirectoryPharmacies
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A vs 503B CompoundingComparisons
- 503A Compounding Pharmacy DirectoryPharmacies
- Why Compounded GLP-1 Access Differs by StateJournal
Related coverage
- GLP-1 Prior Authorization: What Plans Ask For and How to Prepare
- Is compounded tirzepatide legal in 2026?
- Additives, salt forms and a chemistry problem
- Semaglutide providers compared
- Cheapest semaglutide online
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Mochi Health vs Ro
- Mochi Health vs Shed
Semaglutide Ranked. “Is Compounded Semaglutide Legal in 2026?.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/is-compounded-semaglutide-legal-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.